繁 | EN
Policy Address 2025: Government Policy Briefing for HKAPI Members
HKAPI hosted an exclusive policy briefing for our members with officials from the Health Bureau, Department of Health, Hospital Authority, and GBAICTI.

On 26 September, HKAPI hosted an exclusive policy briefing for its members with presentations from officials of the Health Bureau, Department of Health, Hospital Authority, and GBAICTI. The briefing highlighted key initiatives from the recent Policy Address impacting the pharmaceutical industry, including expedited drug development in the Loop, promotion of life and health technology, and enhanced cancer prevention and treatment.

We would like to extend our sincere gratitude to the government for this informative and engaging briefing:

  1. Ms Elaine MAK, Deputy Secretary for Health, Health Bureau;
  2. Mr Michael YIM, Chief Pharmacist 2, Department of Health;
  3. Mr William CHUI, Chief Pharmacist, Hospital Authority;
  4. Mr Terence CHAM, Chief Manager (Business Support Services), Hospital Authority;
  5. Dr Isaac LI, Senior Manager (Clinical Effectiveness), Hospital Authority; and
  6. Prof Bernard CHEUNG, Chief Executive Officer, GBAICTI.
Mr William Chui shared key initiatives of the recent Policy Address, including expediting enlistment of innovative medicine.
Ms. Elaine Mak emphasized the Bureau's commitment to enhancing efficiency, improving coordination, and removing red tape to create long-term value.
Members had the opportunity to engage in a Q&A session covering topics such as drug approval processes, access to Real World Evidence data, clinical trial facilitation, and sustainable industry investment.
During the Q&A session, HKAPI members proactively raised questions regarding the key initiatives from the recent Policy Address impacting the pharmaceutical industry.
Mr. Michael Yim, Chief Pharmacist 2 of the Department of Health, added that the DH is receptive to drug registration applications supported by real-world evidence.

Government representatives expressed a strong willingness to work closely with the pharmaceutical industry. As Ms Elaine Mak, Deputy Secretary for Health shared: 

“We believe direct channels for engagement are important. Setting up working groups and platforms would help expedite inquiries and flag issues efficiently. We welcome suggestions on closer collaboration. Efficiency and shared understanding of value are key.”

Dedicated to enhancing the well-being of the Hong Kong population, the Association makes recommendations on healthcare policies and fosters collaboration among our member companies, the government, and the community. Through our various Project Teams and Working Groups, we collaborate closely with all relevant stakeholders, including government authorities, to advance the pharmaceutical industry’s vital role in Hong Kong.

Please stay tuned for further updates and opportunities for collaboration.

Preserving Trust: AI and Data Privacy in Healthcare
Close Bitnami banner
Bitnami